RU2654596C2 - Композиции коктейля, содержащие антибактериальные фаги, и способы их применения - Google Patents

Композиции коктейля, содержащие антибактериальные фаги, и способы их применения Download PDF

Info

Publication number
RU2654596C2
RU2654596C2 RU2014141941A RU2014141941A RU2654596C2 RU 2654596 C2 RU2654596 C2 RU 2654596C2 RU 2014141941 A RU2014141941 A RU 2014141941A RU 2014141941 A RU2014141941 A RU 2014141941A RU 2654596 C2 RU2654596 C2 RU 2654596C2
Authority
RU
Russia
Prior art keywords
bacteriophage
composition
seq
strains
strain
Prior art date
Application number
RU2014141941A
Other languages
English (en)
Russian (ru)
Other versions
RU2014141941A (ru
Inventor
МЕНДЕС Жуау Жуау Дуарте АЛВЕС
ЛЕАНДРО Клара Исабель РОДРИГЕС
КОРТЕ-РЕАЛ София ВОЛКЕР
Original Assignee
Текнифар-Индустриа Текника Фармасеутика С.А.
Технофаге, Инвестигасао Е Десенволвименто Эм Биотекнология, Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Текнифар-Индустриа Текника Фармасеутика С.А., Технофаге, Инвестигасао Е Десенволвименто Эм Биотекнология, Са filed Critical Текнифар-Индустриа Текника Фармасеутика С.А.
Publication of RU2014141941A publication Critical patent/RU2014141941A/ru
Application granted granted Critical
Publication of RU2654596C2 publication Critical patent/RU2654596C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B2017/320004—Surgical cutting instruments abrasive
    • A61B2017/320008—Scrapers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
RU2014141941A 2012-03-19 2013-03-19 Композиции коктейля, содержащие антибактериальные фаги, и способы их применения RU2654596C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612531P 2012-03-19 2012-03-19
US61/612,531 2012-03-19
PCT/PT2013/000016 WO2013141730A1 (en) 2012-03-19 2013-03-19 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
RU2014141941A RU2014141941A (ru) 2016-05-20
RU2654596C2 true RU2654596C2 (ru) 2018-05-21

Family

ID=48534472

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014141941A RU2654596C2 (ru) 2012-03-19 2013-03-19 Композиции коктейля, содержащие антибактериальные фаги, и способы их применения

Country Status (13)

Country Link
US (1) US9962419B2 (enExample)
EP (1) EP2833899B1 (enExample)
JP (1) JP6186427B2 (enExample)
CN (1) CN104519893B (enExample)
AU (1) AU2013235883B2 (enExample)
BR (1) BR112014023321B1 (enExample)
CA (1) CA2867418C (enExample)
DK (1) DK2833899T3 (enExample)
ES (1) ES2814024T3 (enExample)
PT (1) PT2833899T (enExample)
RU (1) RU2654596C2 (enExample)
SG (1) SG11201405829WA (enExample)
WO (1) WO2013141730A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2794585C2 (ru) * 2021-07-13 2023-04-21 Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии И Реабилитологии" (Фнкц Рр) Способ лечения и профилактики рецидивов нозокомиальной пневмонии

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
WO2016066722A2 (en) * 2014-10-28 2016-05-06 Ian Humphery-Smith Bacteriophage combinations for human or animal therapy
US10455983B2 (en) 2015-09-10 2019-10-29 Prince Castle LLC Modular food holding system
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
WO2017180862A1 (en) * 2016-04-13 2017-10-19 Northeast Ohio Medical University Gpnmb compositions for treatment of skin wounds
WO2018106135A2 (en) 2016-12-05 2018-06-14 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
JP7370867B2 (ja) 2017-02-13 2023-10-30 アルマタ・ファーマシューティカルズ・インコーポレーテッド 療法バクテリオファージ組成物
US20210065844A1 (en) * 2017-09-05 2021-03-04 Adaptive Phage Therapeutics, Inc. Methods to determine the sensitivity profile of a bacterial strain to a therapeutic composition
MX2020004251A (es) * 2017-10-19 2021-05-27 Mona E Buice Composición tópica para cicatrización mejorada de heridas abiertas.
CA3085314A1 (en) * 2017-12-11 2019-06-20 Adaptive Phage Therapeutics, Inc. Phage dispensing system
JP2021508740A (ja) * 2018-01-02 2021-03-11 アルマタ・ファーマシューティカルズ・インコーポレーテッド Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染症を処置するための治療的バクテリオファージ組成物
CN109082414B (zh) * 2018-06-29 2020-11-13 浙江工业大学 一种金黄色葡萄球菌噬菌体及应用
MX2021000889A (es) 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
CN109730235A (zh) * 2019-02-01 2019-05-10 珠海横琴普罗恩能医用食品有限公司 一种用于医用食品的防腐剂
US12576118B2 (en) 2019-05-21 2026-03-17 University of Pittsburgh—of the Commonwealth System of Higher Education Bacteriophages for the treatment of tuberculosis
JP2023523319A (ja) 2020-04-27 2023-06-02 アルマタ・ファーマシューティカルズ・インコーポレーテッド シュードモナス感染症を処置するためのバクテリオファージ組成物
CN111643724B (zh) * 2020-07-01 2022-01-28 南京大学 一种载有噬菌体和酸性成纤维细胞生长因子的水凝胶伤口敷料的制备方法及其应用
WO2022013314A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh Bacteriophage cocktails and uses thereof
WO2022013318A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh New mosaic bacteriophages and uses thereof
CN112251439B (zh) * 2020-10-26 2022-06-21 齐鲁师范学院 拟南芥高温诱导启动子pHTG1及其重组载体
CN112301001B (zh) * 2020-11-03 2022-10-14 华中农业大学 金黄色葡萄球菌噬菌体lsa2311及其应用
CN113201458B (zh) * 2020-12-21 2022-05-27 青岛诺安百特生物技术有限公司 一种提高噬菌体制剂稳定性的组合物及其应用
AU2022272135A1 (en) * 2021-05-12 2024-01-04 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
WO2022261498A1 (en) * 2021-06-11 2022-12-15 Integrated Pharma Services, Llc Device and methods for acne therapeutics: antibacterial bacteriophages and engineered lysins
DE202022102100U1 (de) 2022-04-20 2022-04-27 Prabhakar Ramesh Bhandari Synergistische antibiotische pharmazeutische Zusammensetzung zur Behandlung von Staphylococcus aureus-Infektionen
EP4626449A1 (en) * 2022-11-28 2025-10-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Acinetobacter baumannii phages
WO2025104708A1 (en) 2023-11-16 2025-05-22 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Method for determining the susceptibility of bacteria to bacteriophages

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080823A2 (en) * 2002-03-25 2003-10-02 University Of Warwick Bacteriophages useful for therapy and prophylaxis of bacterial infections
WO2010090542A2 (en) * 2009-02-06 2010-08-12 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Antibacterial phage, phage peptides and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699322B2 (en) 1994-04-05 1998-12-03 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6138401A (en) 1999-06-25 2000-10-31 Duncan; Franklin R. Fish hook remover
US20050095222A1 (en) 2003-10-29 2005-05-05 Taro Suzuki Allergen inhibitor, allergen-inhibiting method, allergen-inhibiting fiber and allergen-inhibiting sheet
EP1812025B1 (en) 2004-11-02 2012-09-05 Chr. Hansen A/S Stabilized bacteriophage formulations
MX2007005279A (es) 2004-11-02 2008-03-11 Gangagen Life Sciences Inc Composiciones de bacteriofagos.
CA2593992A1 (en) 2004-12-06 2006-06-15 Rodney M. Donlan Inhibition of biofilm formation using bacteriophage
US20080260697A1 (en) 2005-05-26 2008-10-23 Gangagen Life Sciences Inc. Bacterial Management in Animal Holding Systems
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
RU2614114C2 (ru) * 2010-09-17 2017-03-22 Текнифар-Индустриа Текника Фармасьютика, С.А Бактериофаги, фаговые пептиды и способы их применения

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080823A2 (en) * 2002-03-25 2003-10-02 University Of Warwick Bacteriophages useful for therapy and prophylaxis of bacterial infections
WO2010090542A2 (en) * 2009-02-06 2010-08-12 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Antibacterial phage, phage peptides and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDER SULAKVELIDZE et al., Bacteriophage Therapy, Antimicrobial Agents and Chemotherapy, Mar. 2001, Vol. 45, No. 3, pp. 649-659. *
BENJAMIN A. LIPSKY et al., Diagnosis and Treatment of Diabetic Foot Infections, Journal of the American Podiatric Medical Association, March/April 2005, Vol 95, No 2, pp.183-210. *
BENJAMIN A. LIPSKY et al., Diagnosis and Treatment of Diabetic Foot Infections, Journal of the American Podiatric Medical Association, March/April 2005, Vol 95, No 2, pp.183-210. ALEXANDER SULAKVELIDZE et al., Bacteriophage Therapy, Antimicrobial Agents and Chemotherapy, Mar. 2001, Vol. 45, No. 3, pp. 649-659. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2794585C2 (ru) * 2021-07-13 2023-04-21 Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии И Реабилитологии" (Фнкц Рр) Способ лечения и профилактики рецидивов нозокомиальной пневмонии
RU2818910C1 (ru) * 2023-08-30 2024-05-07 Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии И Реабилитологии" (Фнкц Рр) Способ профилактики инфекций, связанных с оказанием медицинской помощи, у пациентов, находящихся в хроническом критическом состоянии

Also Published As

Publication number Publication date
CA2867418C (en) 2020-03-10
SG11201405829WA (en) 2014-10-30
BR112014023321A2 (pt) 2022-02-01
DK2833899T3 (da) 2020-09-28
AU2013235883A1 (en) 2014-10-02
CN104519893A (zh) 2015-04-15
EP2833899B1 (en) 2020-06-24
WO2013141730A1 (en) 2013-09-26
US9962419B2 (en) 2018-05-08
HK1207002A1 (en) 2016-01-22
EP2833899A1 (en) 2015-02-11
RU2014141941A (ru) 2016-05-20
PT2833899T (pt) 2020-09-15
AU2013235883B2 (en) 2018-01-04
JP6186427B2 (ja) 2017-08-23
CA2867418A1 (en) 2013-09-26
ES2814024T3 (es) 2021-03-25
US20150150919A1 (en) 2015-06-04
BR112014023321B1 (pt) 2022-06-14
JP2015512384A (ja) 2015-04-27
CN104519893B (zh) 2020-02-07

Similar Documents

Publication Publication Date Title
US9962419B2 (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
Bowler et al. Wound microbiology and associated approaches to wound management
JP6944399B2 (ja) プロバイオティクス細菌
Aswathanarayan et al. Biofilm-associated infections in chronic wounds and their management
Hayashi et al. Effects of ozone nano-bubble water on mucositis induced by cancer chemotherapy
JP2016519667A (ja) 創傷治癒のための組成物および使用方法
KR20120034626A (ko) 플루오로-퀴놀론을 사용하여 폐의 세균성 감염을 치료하는 방법
US10285938B2 (en) Composition for the treatment of burns, diabetic wounds, other types of wounds and subsequently greatly reduced scarring
Gencay Topical sevoflurane: An alternative treatment for pressure ulcers
JP2024108161A (ja) 皮膚疾患の処置のためのペプチド
CN110917339B (zh) 一种溶葡萄球菌酶凝胶剂及其在mrsa感染创面中的应用
HK1207002B (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
CN1911442B (zh) 一种用于防治创面感染的溶葡萄球菌酶冻干粉剂
US20240156860A1 (en) Method of treating infected and noninfected burn wounds
Johnson Immune Modulatory and Antimicrobial Properties of Mesenchymal Stromal Cells Delivered Systemically
Hillebrand et al. In vitro efficacy of four potential antimicrobial substances against Klebsiella species and Streptococcus uberis isolated from bovine mastitis
Li et al. Antimicrobial effects of compound Huangbai liquid on staphylococcus aureus, Escherichia coli and MRSA: clinical, bacterial, and animal experimental studies
TW201622741A (zh) 狗圍肛腺瘤之治療方法
Wang et al. Topically applied bacteriophage to control multi-drug
Gajakosh Prophylactic Antibiotic and Post Operative Surgical Wound Infection
TWI578994B (zh) 燒燙傷口癒合組合物
Das Management of Second Degree Burns: A Comparative Study Between Silver Impregnated Hydrofiber Dressings and Conventional Dressings
Sreejith Effectiveness of Prophylactic Single Dose Antibiotic Versus Multiple Dose Post-Operative Antibiotics in Preventing Surgical Site Infections in Clean and Clean Contaminated Surgeries-A Comparitive Study
Burrell et al. Edward E Tredget, Robert Rennie
Górski Prospects of Phage Application in the Treatment of Acne Caused by